Celgene Corp (CELG) 131.25 $CELG 5 Top Stocks Riding

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2015 at 2:52 AM

Celgene Corp (CELG) 131.25 $CELG

5 Top Stocks Riding Earnings Season To Big Gains
at Investor's Business Daily - Fri Jul 31, 5:21PM CDT
Earnings season has been unkind to a number of recent leaders like Taser International (TASR), but it has spurred plenty of other stocks to breakouts or big gains. The market uptrend is still under pressure, but these stocks aren't letting that get...
VRX: 257.53 (+3.25), ELLI: 78.45 (+9.32), JAZZ: 192.24 (+1.86), UHS: 145.23 (+3.79), TASR: 27.22 (-0.89), CELG: 131.25 (-0.63)

AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 9:30AM CDT
AstraZeneca's (AZN) second-quarter 2015 core earnings of $1.21 per American Depositary Share were significantly above the Zacks Consensus Estimate of 52 cents.
ISIS: 54.93 (+1.76), AZN: 33.79 (+0.05), CELG: 131.25 (-0.63)

Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)

Q2 Earnings Season Halftime Report
ESTMZ - Wed Jul 29, 1:47PM CDT
And just like that, we’re already at the midpoint of the second quarter earnings season. Technically, we’re past that, with 264 S&P 500 companies reporting. As usual, we are in much better standing in regards to growth than we were at the...
VLO: 65.60 (+1.37), SPY: 210.50 (-0.32), GILD: 117.86 (-0.04), FB: 94.01 (-1.20), XOM: 79.21 (-3.80), CVX: 88.48 (-4.55), TWTR: 31.01 (-0.46), AAPL: 121.30 (-1.07), GOOG: 625.61 (-6.98), CELG: 131.25 (-0.63)

Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 117.86 (-0.04), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)

Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 318.78 (+1.78), F: 14.83 (-0.27), RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), AMGN: 176.59 (+4.90), DD: 55.76 (+0.17), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), UPS: 102.36 (+0.96), CELG: 131.25 (-0.63)

Amp Up Your Portfolio With These Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 29, 8:41AM CDT
Source: Flickr user Stockmonkeys.com. Biotech stocks have been among the market's brightest shining stars, but many of these stocks have already made big moves higher. As a result, investors could be wondering if there are any companies in the...
GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)

Celgene begins tender offer for Receptos at USD232.00 per share
M2 - Wed Jul 29, 5:05AM CDT
Pharmaceutical company Celgene (NasdaqGS:CELG) disclosed on Tuesday that it has commenced its tender offer for all outstanding shares of common stock of Receptos (NasdaqGS:RCPT) at a price of USD232.00 per share, net to the seller in cash, without interest and less required withholding taxes.
RCPT: 227.86 (+0.38), CELG: 131.25 (-0.63), CELGZ: 2.04 (+0.01)

NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 72.77 (+1.47), NK: 30.60 (-0.90), ALXN: 197.44 (-1.85), RCPT: 227.86 (+0.38), AMGN: 176.59 (+4.90), JUNO: 48.92 (+1.15), CELG: 131.25 (-0.63)

Celgene (CELG) Crosses Pivot Point Resistance at $133.64
Comtex SmarTrend(R) - Tue Jul 28, 9:35AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $132.37 today and has reached the first level of resistance at $133.64. Investors may be interested in a cross of the next upside pivot targets of $134.71 and $137.05.
CELG: 131.25 (-0.63)

Celgene Corporation Commences Tender Offer for Receptos, Inc.
Business Wire - Tue Jul 28, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
RCPT: 227.86 (+0.38), CELG: 131.25 (-0.63), CELGZ: 2.04 (+0.01)

3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)

Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.73%
Comtex SmarTrend(R) - Mon Jul 27, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 131.25 (-0.63)

Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.73% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 131.25 (-0.63)

Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 318.78 (+1.78), GRUB: 31.71 (+0.07), XBI: 255.44 (+2.98), IBB: 382.53 (+3.73), REGN: 553.66 (+6.56), CELG: 131.25 (-0.63)

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMGN: 176.59 (+4.90), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19), CELG: 131.25 (-0.63)

FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 318.78 (+1.78), COF: 81.30 (-0.20), GILD: 117.86 (-0.04), FCX: 11.75 (-0.09), RCPT: 227.86 (+0.38), CLF: 2.52 (-0.13), REGN: 553.66 (+6.56), CELG: 131.25 (-0.63)

1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 117.86 (-0.04), IBB: 382.53 (+3.73), CELG: 131.25 (-0.63)

Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 36.06 (+0.48), BIIB: 318.78 (+1.78), BBC: 36.17 (+0.44), ADRO: 26.22 (+0.43), KITE: 72.77 (+1.47), NK: 30.60 (-0.90), ALXN: 197.44 (-1.85), RCPT: 227.86 (+0.38), TEVA: 69.02 (-0.05), JUNO: 48.92 (+1.15), CELG: 131.25 (-0.63)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...